Figure 4

Effect of roflumilast and indacaterol on TGFβ1-induced αSMA expression and FN secretion in NHLF. (A) NHLF were pretreated with compound or vehicle control for 1 h, treated with TGFβ1 (10 ng/mL) for 48 h, and αSMA expression quantitated by flow cytometry. Data is reported as the percentage of TGFβ1 vehicle-treated cells, mean ± SEM for n = 4. (B) NHLF were pretreated with compound or vehicle control for 1 h, treated with TGFβ1 (10 ng/mL) for 48 h and FN secretion quantitated. Data is reported as the percentage of TGFβ1 vehicle-treated cells, mean ± SEM for n = 4-6. ROF: roflumilast, INDA: indacaterol. *p < 0.05, **p < 0.01, ***p < 0.001 as compared to TGFβ1 vehicle-treated cells, #p < 0.05 and ###p < 0.001 as compared to roflumilast treated cells, &p < 0.05 and &&p < 0.01 as compared to indacaterol treated cells.